CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio” or “the Company”), a leader in B Cell Medicines (BCMs), today announced the closing of its $92M Series C financing. The round includes ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics (“Aviceda”), a private, clinical-stage biotech company focused on developing next-generation immunomodulators with a proprietary High Affinity ...
SYDNEY--(BUSINESS WIRE)-- AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 ...
For all the turmoil these days, the U.S. stock market remains extremely attractive to investors around the world, simply because of its sheer size and liquidity. But it’s still quite difficult for ...
AT&T’s Series C preferred ADS (under ticker T.PR.C) provides cumulative dividends yielding 6.26%, offering stable income backed by reliable telecom cash flows. AT&T reported strong Q1 2025 revenues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results